Jump to main content
Jump to site search

Issue 33, 2019
Previous Article Next Article

Dual-action organoplatinum polymeric nanoparticles overcoming drug resistance in ovarian cancer

Author affiliations

Abstract

Drug resistance to the conventional platinum chemotherapy remains a major challenge for treating ovarian cancer. Herein, we present a novel approach to overcome the drug resistance by utilizing “dual-action” organometallic polymeric nanoparticles (OPNPs). The OPNPs were formed by the assembly of the organoplatinum payloads and the anionic block copolymer, methoxy polyethylene glycol-block-polyglutamic acid (MPEG5k-PGA50). The OPNPs enhance the solubility and biocompatibility of the hydrophobic organoplatinum payloads. The OPNPs enter the cancer cells via endocytosis, and the payloads loaded in the core of the nanoparticles are slowly released under the acidic conditions of endosomes. Unlike conventional platinum therapeutics, the organoplatinum compound exhibits a “dual-action” attack by triggering nuclear DNA damage and mitochondrial damage. As a result, drug-resistant ovarian cancer cells become vulnerable to the organoplatinum payloads.

Graphical abstract: Dual-action organoplatinum polymeric nanoparticles overcoming drug resistance in ovarian cancer

Back to tab navigation

Supplementary files

Publication details

The article was received on 22 Apr 2019, accepted on 10 Jul 2019 and first published on 10 Jul 2019


Article type: Paper
DOI: 10.1039/C9DT01683J
Dalton Trans., 2019,48, 12451-12458

  •   Request permissions

    Dual-action organoplatinum polymeric nanoparticles overcoming drug resistance in ovarian cancer

    A. M. D. S. Jayawardhana, Z. Qiu, S. Kempf, H. Wang, M. Miterko, D. J. Bowers and Y. Zheng, Dalton Trans., 2019, 48, 12451
    DOI: 10.1039/C9DT01683J

Search articles by author

Spotlight

Advertisements